Detailed information for compound 2241869

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 508.331 | Formula: C32H40N6
  • H donors: 1 H acceptors: 3 LogP: 7.17 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 2
  • SMILES: CC(c1ccc(c(c1)N1CCc2c(C1)c(nc(n2)c1c(C)ccc2c1c(C)[nH]n2)N1CCCC[C@@H]1C)C)C
  • InChi: InChI=1S/C32H40N6/c1-19(2)24-12-10-20(3)28(17-24)37-16-14-26-25(18-37)32(38-15-8-7-9-22(38)5)34-31(33-26)29-21(4)11-13-27-30(29)23(6)35-36-27/h10-13,17,19,22H,7-9,14-16,18H2,1-6H3,(H,35,36)/t22-/m0/s1
  • InChiKey: SMYHNFUQAVSHCL-QFIPXVFZSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens complement component 5a receptor 1 No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus multilocularis G-protein coupled receptor, putative complement component 5a receptor 1 350 aa 293 aa 22.2 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma brucei proteasome subunit beta type-5, putative 0.0255 1 0.5
Giardia lamblia Proteasome subunit beta type 5 precursor 0.0255 1 0.5
Plasmodium vivax proteasome subunit beta type-5, putative 0.0255 1 0.5
Toxoplasma gondii proteasome subunit beta type, putative 0.0255 1 0.5
Plasmodium falciparum proteasome subunit beta type-5 0.0255 1 0.5
Mycobacterium leprae proteasome (beta subunit) PrcB 0.0255 1 0.5
Echinococcus multilocularis proteasome (prosome, macropain) 0.0255 1 1
Trypanosoma cruzi proteasome subunit beta type-5, putative 0.0255 1 0.5
Mycobacterium ulcerans proteasome PrcB 0.0255 1 0.5
Schistosoma mansoni proteasome catalytic subunit 3 (T01 family) 0.0255 1 1
Entamoeba histolytica proteasome subunit beta type 5 precursor, putative 0.0255 1 0.5
Mycobacterium tuberculosis Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. 0.0255 1 0.5
Loa Loa (eye worm) proteasome A-type and B-type family protein 0.0255 1 0.5
Leishmania major proteasome beta 5 subunit, putative 0.0255 1 0.5
Trypanosoma cruzi proteasome subunit beta type-5, putative 0.0255 1 0.5
Echinococcus granulosus proteasome prosome macropain 0.0255 1 1
Trichomonas vaginalis Family T1, proteasome beta subunit, threonine peptidase 0.0255 1 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 1 nM BindingDB_Patents: FLIPR Assay. Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Galpha 15 protein on the FLIPR (Fluorescent Imaging Plate Reader) Tetra system. Cells were maintained in culture media containing DMEM (Dulbecco's Modified Eagle Medium) with 4.5 g/L glucose, 10% fetal bovine serum, 100 U/mL, 1x non-essential amino acid, and 250 ug/mL G418 (Geneticin). Prior to testing of compounds, cells were plated at 10,000 cells/well in clear bottom 384-well black plate, and incubated overnight at 37C. with 5% CO2. On the day of experiment, culture media was removed, and replaced with assay buffer HBSS (Hanks' Balanced Salt Solution) with 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 0.1% BSA (bovine serum albumin) BSA containing calcium 5 dye (Molecular Devices) and 2.5 mM probenecid. After 1 hour incubation at 37C., 5% CO2 for 60 min, cells were pre-incubated with compounds for 30 minutes. ChEMBL. No reference
IC50 (binding) = 1 nM BindingDB_Patents: FLIPR Assay. Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Galpha 15 protein on the FLIPR (Fluorescent Imaging Plate Reader) Tetra system. Cells were maintained in culture media containing DMEM (Dulbecco's Modified Eagle Medium) with 4.5 g/L glucose, 10% fetal bovine serum, 100 U/mL, 1x non-essential amino acid, and 250 ug/mL G418 (Geneticin). Prior to testing of compounds, cells were plated at 10,000 cells/well in clear bottom 384-well black plate, and incubated overnight at 37C. with 5% CO2. On the day of experiment, culture media was removed, and replaced with assay buffer HBSS (Hanks' Balanced Salt Solution) with 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 0.1% BSA (bovine serum albumin) BSA containing calcium 5 dye (Molecular Devices) and 2.5 mM probenecid. After 1 hour incubation at 37C., 5% CO2 for 60 min, cells were pre-incubated with compounds for 30 minutes. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.